Bullish
Johnson & Johnson's stock rises 0.21% to $271.22 amid positive Caplyta trial results.
Johnson & Johnson's stock experienced a slight increase following favorable results from a Caplyta trial. The stock closed at $271.22 on September 25, 2026, up 0.21% from the previous close. The trial results are expected to positively impact the company's financial performance.
Key points
- Caplyta trial results show positive outcomes, potentially boosting revenue.
- Stock trading volume remains consistent, indicating steady investor interest.
- No significant changes in institutional holdings reported recently.
Sources
AI-generated from public news sources. Not financial advice.
